Market Analysis and Insights: Global Gene Panel Market
A gene panel is a test that analyzes multiple genes at once for cancer-associated mutations.
The global Gene Panel market size is projected to reach US$ 3365.6 million by 2028, from US$ 1186.3 million in 2021, at a CAGR of 15.6% during 2022-2028.
In 2017, North America dominated the market, followed by Europe. The large share of the North American market can be majorly attributed to the government support for genomics research. Other growth factors include the presence of leading NGS providers, growing research on cancer and inherited rare diseases, and increasing number of NGS-based & clinical applications in the region.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Gene Panel market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Gene Panel market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Gene Panel market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Gene Panel market.
Global Gene Panel Scope and Market Size
Gene Panel market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Gene Panel market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Amplicon-based Approach
Hybridization-based Approach
Segment by Application
Cancer Risk Assessment
Diagnosis of Congenital Diseases
Pharmacogenetics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Illumina
Thermo Fisher
Agilent
Qiagen
Eurofins Scientific
BGI
Roche
Integrated Dna Technologies
Genewiz
Novogene
Personalis
Gatc Biotech
Archerdx